Pembrolizumab (pembro) as first-line therapy in cisplatin-ineligible advanced urothelial cancer (UC): Outcomes from KEYNOTE-052 in senior patients (pts) with poor performance status Meeting Abstract
| Authors: | Grivas, P.; Plimack, E.; Balar, A. V.; Castellano, D.; O'Donnell, P. H.; Bellmunt, J.; Powles, T.; Hahn, N.; de Wit, R.; Bajorin, D.; Ellison, M. C.; Frenkl, T.; Keefe, S. M.; Vuky, J. |
| Abstract Title: | Pembrolizumab (pembro) as first-line therapy in cisplatin-ineligible advanced urothelial cancer (UC): Outcomes from KEYNOTE-052 in senior patients (pts) with poor performance status |
| Meeting Title: | 42nd ESMO Congress (ESMO 2017) |
| Journal Title: | Annals of Oncology |
| Volume: | 28 |
| Issue: | Suppl. 5 |
| Meeting Dates: | 2017 Sep 8-12 |
| Meeting Location: | Madrid, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2017-09-01 |
| Start Page: | mdx371.011 |
| Language: | English |
| ACCESSION: | WOS:000411324002047 |
| PROVIDER: | wos |
| DOI: | 10.1093/annonc/mdx371.011 |
| Notes: | Meeting Abstract: 857P -- Appears on page 301 of the abstract book -- Source: Wos |
